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Psychological Fronts in SARS and Human Swine
Inﬂuenza
Joseph J.Y. Sung*. Department of Medicine and Therapeutics,
Prince of Wales Hospital, The Chinese University of Hong Kong,
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STOA3 Global Strategy in the Usage of Antibiotics
Raul E. Isturiz *. Department of Medicine, Infectious Diseases,
Centro Medico de Caracas, Caracas, Venezuela
The kind and severity of infectious diseases, the host, the ac-
cessibility of drugs and the resistance patterns of causative
microbes are the main drivers for the modern use of antibiotics.
Although advances in rapid etiological diagnosis, clinical severity
indexes and susceptibility/resistance proﬁles have been made,
major deﬁciencies still exist in vaccination and other preventive
measures, immediate bedside diagnosis, preservation of host
defenses and other functions, universal availability of quality
antimicrobials, appropriate use of currently available antibiotics
and development of newer, more active ones. Research is re-
quired in all those areas as well as in veterinary medicine and
agriculture to determine the exact contribution that each sector
provides to the development of antimicrobial resistance. A global
strategy for the optimal use of these apparently non-renewable
resources may be drafted now, but implementation will need
a concerted global effort that extends beyond the practice of
medicine.
STOA4 Viral Hepatitis B in China: The Research Findings
and Clinical Application
Ji-dong Jia*. Liver Research Center, Beijing Friendship Hospital,
Capital Medical University, Beijing, China
Chronic hepatitis B infection is a very important health problem
in China, which is carrying an enormous economic and social
burdens. The major routs of chronic hepatitis B infection in China
are mother-infant vertical transmission and early childhood hori-
zontal transmission. After more than 10 years implementation of
universal vaccination against hepatitis B in newborns and safety
injection in health care settings, the prevalence of HBsAg in
general population has decreased from 9.75% to around 7%. In
China, patients with hepatitis are cared by either hepatologists
or physicians of infectious diseases. The Chinese Society of Hep-
atology, and Chinese Society of Infectious Diseases jointly issued
an evidence-based guideline on the prevention and treatment of
chronic hepatitis B in 2005. This guideline concisely describes
the virology, epidemiology, natural history and prevention, as
well as diagnosis and management of chronic hepatitis B. It
also highlights the importance of active viral replication in dis-
ease progression in chronic HBV infection and explicitly states
the necessity of antiviral therapy in patient care. The corner-
stone of anti-hepatitis B therapy is optimal use of interferons
or nucleos(t)ide analogs in those patients with actively viral
replication and elevated serum transaminase levels. Through an
independent continue medical educational agency, a panel of
selected speakers were trained to give well-formatted talks on
the key points of the guideline in over 60 major cities across
China. This educational campaign among health care providers
has greatly improved the awareness and the stand of care for
antiviral therapy.
STOA5 Refractory MRSA Infection in Hospital
Po-Ren Hsueh*. Divisions of Clinical Microbiology and Infectious
Diseases, Departments of Laboratory, Medicine and Internal
Medicine, National Taiwan University Hospital, National Taiwan;
University College of Medicine, Taipei, Taiwan
Infections due to methicillin-resistant Staphylococcus aureus
(MRSA) are increasingly serious in recent decades in both com-
munity and hospital settings. Glycopeptides (vancomycin and
teicoplanin) represent the gold standard for therapy of invasive
infections caused by MRSA. However, the problems with gly-
copeptides use in the management of MRSA infection are notably
rising. These include MIC creep, emergence of vancomycin-
intermediate and -resistant MRSA (VISA and VRSA), increasing
reports of clinical failures among speciﬁc patient populations,
toxicity, inadequate dosing for serious infections, underscore
the need for alternative therapies. Older agents with favor-
able in vitro potency available in oral and/or intravenous forms
include trimethoprim-sulfamethoxazole, rifampin, fusidic acid,
fosfomycin, and clindamycin. However, limited clinical data exist
to support their routine use as initial therapy in the treatment of
invasive disease. Newer treatment options for MRSA include line-
zolid, quinupristin-dalfopristin, daptomycin, cftobiprole, tigecy-
cline, and nemonoxacin. With the exception of linezolid, these
newer agents require intravenous administration. Combination
therapy is mandatory for selected invasive diseases refractory
to standard monotherapies. These diseases include endocarditis,
meningitis, septic arthritis, prosthetic device infections, and
other recalcitrant MRSA Infections. Some novel agents are under
investigation, consisting of oritavancin, dalbavancin, telavancin,
and ceftobiprole. Daptomycin is a promising antibiotic for the
treatment of patients with right-sided endocarditis and bacter-
aemia. However, development of hematogenous spread of MRSA
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